Forxiga also reduced the relative risk of death ... which have yet to extend the use of their brand into heart failure and CKD but currently claim almost 60% market share among SGLT2 drugs used ...

AZ is also putting Forxiga through its paces in heart failure in combination with other drugs, including its mineralocorticoid receptor modulator AZD9977 and selective endothelin A antagonist ...